Bottle of Canxiol Cannabidiol Oral Solution 150 mg/mL, 28 mL, with a dropper cap

What is Canxiol?

Canxiol is a Cannabidiol oral solution containing Cannabidiol 150mg/ml for the management of mild to moderate anxiety in conjunction with cognitive behavior therapy. To be prescribed by Psychiatrists only.

CANNABIDIOL (SYNTHETIC)

No withdrawal symptoms. Non-psychoactive, with no known potential for dependence or addiction.

PROPRIETARY NANODISPERSION ORAL SOLUTION

Rapid aqueous distribution upon mixing with water. Easy to use and titrate with no pill burden.

CLINICALLY TESTED

89% treatment response for Anxiety (HAM-A scale). 60% Improvement in Depression Symptoms (PHQ-9 score) and Sleep quality (PSQI score)

PACKAGING SPECIFICATIONS

Pack Presentation.

Canxiol is available in two pack configurations:

CONFIGURATION 01

14 mL bottle

CONFIGURATION 02

28 mL bottle

Supplied with a tamper-resistant CRC cap and a calibrated 1 mL CRC dropper.

✓ Precise volume gradations (0.25, 0.50, 0.75, 1.0 mL)

Canxiol 14 mL and 28 mL packs with their bottles

Storage Conditions.

IN-USE PACK:

Use within 60 days of first opening the bottle, then discard any remainder.

UNOPENED PACK:

Store at a temperature not exceeding 30ºC. Do not freeze. Protect from light. Store the bottle upright. Keep out of reach of children. Keep the cap tightly closed.

PHARMACEUTICAL DIFFERENTIATION

How Canxiol stands out?

Product Innovation through collaboration
Trademark and IP owner
Synthetic cannabidiol API manufacturingUSDMF #35992
GMP certified Formulation manufacturing
Canxiol 28 mL bottle with dropper cap
  1. 01

    Canxiol contains fully synthetic Cannabidiol, not plant-derived and hence non-psychoactive, with no known potential for abuse, dependance. No withdrawal symptoms

  2. 02

    Canxiol is formulated with pharmaceutical grade synthetic cannabidiol using proprietary nanodispersion technology

  3. 03

    API Manufactured by Biophore in accordance to GMP requirements and has a USDMF No- 35992

  4. 04

    Canxiol is manufactured by Zenara in their facilities with GMP certification from regulatory authorities including the USFDA, EU, MHRA, Turkey, Russia & WHO - GMP certified

How to Administer Canxiol.

Canxiol® should be administered at the dose prescribed by your psychiatrist.

Administer the dose at consistent time with respect to meals preferably 30 minutes after food.

It is recommended to use a calibrated measuring dropper provided along with the pack to measure and deliver the prescribed dose accurately. A household teaspoon or tablespoon is not an adequate measuring device.

Measure the prescribed dose of Canxiol® into the calibrated dropper and add the measured dose to about 150 mL of water. Stir rapidly for at least 10 seconds using a spoon or stirrer and immediately administer the dose orally.

A young woman talking with a psychiatrist who takes notes on a clipboard
Take prescribed dose in the dropper, put into 150mL of water, stir will for 10sec & consume oral.
STEP 01

Prescribed dose

Verify the exact dose as directed by Psychiatrist to be administered 30 mins post meal.

STEP 02

Measure with calibrated dropper

Use only the enclosed calibrated measuring dropper supplied with the pack to draw the accurate volume.

STEP 03

Add & stir rapidly

Add to approx 150ml water and stir rapidly with a spoon or stirrer for at least 10 seconds.

STEP 04

Administer orally

After stirring, immediately consume the entire contents orally.

⚠ IMPORTANT

Do not allow the dropper to touch the water while adding the product. In instance, if the tip of the dropper touches the water, squeeze the dropper & wipe the dropper with a clean absorbent tissue paper, clean cloth and place the dropper back into the bottle.

After use, close the bottle tightly with dropper provided. Store at a temperature not exceeding 30ºC.

Discard any unused Canxiol® remaining 60 days after first opening the bottle.

CLINICAL SCIENTIFIC STUDY

Clinical Trial Data.

Phase III, prospective, double-blind, placebo-controlled, parallel-group, multicentre randomised controlled trial.

178 participants randomised 1:1 (Canxiol & Placebo) across 10 sites in all four regions of India, January to December 2023, for regulatory approval in India

178PARTICIPANTS
1:1RANDOMISATION
10SITES
Jan–Dec 2023TRIAL DURATION

Clinical Trial Data.

CANXIOL® EVIDENCE SUMMARY

A prospective, randomized, double-blind, multicenter comparative study to Evaluate the Efficacy, Safety and Pharmacokinetics of Cannabidiol oral solution versus matching Placebo for treatment of mild to moderate anxiety disorders

PHASE III · RCT · DOUBLE-BLIND · PARALLEL-GROUP
10sites, 4 regions of India
178 randomized89 CBD : 89 Placebo

Significant response, all clinical endpoints

Anxiety, clinician global impression, depressive symptoms, and sleep quality each improved by roughly half to two-thirds from baseline with cannabidiol.

Well-tolerated

41 of 178 participants reported at least one adverse event; none were serious, and none led to treatment discontinuation.

Endpoints

Primary:
GAD-7, HAM-A
Secondary:
CGI-I, CGI-S, PHQ-9, PSQI
Assessed:
Baseline and Visit 9 (end of treatment)
DOSING REGIMEN

150 mg BID in week 1, titrated to 225 mg BID in week 2 and 300 mg BID in week 3, continued for 8 weeks (Visit 9), then tapered to 150 mg QD for 1 week. The dose is added to about 150 mL of water, mixed, and consumed 30 minutes after food.

SECONDARY ENDPOINTS – CLINICIAN-RATED SCALES
CGI-I
00.511.522.533.54
4
1.6
Cannabidiol
3.9
3.9
Placebo
CGI-S
00.511.522.533.54
3.9
2
Cannabidiol
3.9
3.9
Placebo
Baseline Visit 9

Both co-primary endpoints met

GAD-7 − 7.02 pts • HAM-A − 11.9 pts vs. placebo, both p < 0.0001

PRIMARY ENDPOINTS – ANXIETY SCORES IMPROVED SIGNIFICANTLY
GAD-7
02468101214
11.8
4.8
Cannabidiol
11.2
11.8
Placebo
HAM-A
02468101214161820
18.9
7.34
Cannabidiol
18.2
18.9
Placebo
Baseline Visit 9
SECONDARY ENDPOINTS – MOOD & SLEEP IMPROVED ALONGSIDE ANXIETY
PHQ-9
02468101214
11.7
4.53
Cannabidiol
10.9
11.1
Placebo
PSQI
0246810
9.8
3.6
Cannabidiol
8.7
9.3
Placebo
Baseline Visit 9

Gundugurti PR, Banda N, Yadlapalli SS, Narala A, Thatikonda R, Kocherlakota C, Kothapalli KSD. Asian J Psychiatry 2024;97:104073; https://doi.org/10.1016/j.ajp.2024.104073.

SAFETY PROFILE

Adverse Reactions reported in phase 3 clinical trial.

In Phase III randomized clinical trial, the most common adverse reactions that occurred in Canxiol® treated patients with mild to moderate anxiety disorders were fatigue, abdominal pain, abdominal distension, dizziness, diarrhoea, nausea.

Below table lists the adverse reactions that were reported in the randomized controlled trial.

Adverse Reactions in patients treated with Canxiol® in clinical trial

ADVERSE REACTIONSCANXIOL® (N=89) N (%)PLACEBO (N=89) N (%)
Patients with at least one AE28 (15.7)13 (7.3)
Gastrointestinal disorders17 (19.1)6 (6.7)
• Abdominal distension2 (2.2)0
• Abdominal pain2 (2.2)0
• Abdominal pain upper3 (3.4)0
• Constipation1 (1.1)1 (1.1)
• Diarrhoea3 (3.4)0
• Eructation01 (1.1)
• Frequent bowel movements2 (2.2)0
• Nausea5 (5.6)3 (3.4)
• Vomiting01 (1.1)
General disorders and administration site conditions4 (4.5)3 (3.4)
• Fatigue1 (1.1)0
• Pain2 (2.2)0
• Pyrexia1 (1.1)3 (3.4)
Infections and infestations1 (1.1)0
• Nasopharyngitis1 (1.1)0
Nervous system disorders7 (7.9)5 (5.6)
• Dizziness2 (2.2)2 (2.2)
• Dysgeusia1 (1.1)0
• Headache4 (4.5)4 (4.5)
Psychiatric disorder1 (1.1)0
• Libido increased1 (1.1)0
Respiratory, thoracic and mediastinal disorders01 (1.1)
• Cough01 (1.1)

n: Number of patients, %: Percentage of patients

These mild adverse reactions are resolved during continued treatment with Canxiol®, without need for dose adjustment.
CLINICAL PHARMACOLOGY

Drug-drug Interactions.

Comprehensive metabolic and pharmacokinetic interaction guidance for prescribers.

Co-administration with a strong CYP3A4 (Carbamazepine, Efavirenz, Mitotane, Enzalutamide) and CYP2C19 inducer (rifampin) reported to decrease cannabidiol plasma concentrations. Consider an increase in Cannabidiol dosage (based on clinical response and tolerability), when co-administered with a strong CYP3A4 and/or CYP2C19 inducer.

ADME PARAMETERS

Pharmacokinetics.

Absorption

The single dose pharmacokinetics of Cannabidiol following oral administration of Canxiol® to healthy volunteers under fasting and fed conditions is provided in the table below.

Single Dose Pharmacokinetics of CANXIOL® (under fasting and fed conditions)

PARAMETERCANXIOL®, 300 MG (FASTING)CANXIOL®, 300 MG (FED)
Cmax (ng/mL)229.338306.108
Tmax (h)0.9942.738
AUCinf (ng*hr/mL)535.8401626.432
T1/2 (h)3.5716.938

Meal Effect: Coadministration of Canxiol® with a high-fat/high-calorie meal increased Cmax by about 1.3 folds, AUC by about 3 folds compared with the fasted state in healthy volunteers.

DISTRIBUTION

Volume Profile

The volume of distribution of Canxiol® in healthy volunteers in fed and fasting conditions is about 1846 L and 2884 L respectively.

METABOLISM

Hepatic Pathways

Cannabidiol is metabolized in the liver and the intestine by CYP2C19 and CYP3A4 enzymes, and 5′-diphosphoglucuronosyltransferase (UGT) UGT1A7, UGT1A9, and UGT2B7 isoforms. Converted to major metabolites 7-Hydroxy Cannabidiol and 7-carboxy Cannabidiol.

ELIMINATION

Clearance & Half-life

The single-dose half-life of Canxiol® in fasted condition is about 3.5h and in fed condition is about 7h.

EXCRETION

Renal Clearance

Cannabidiol and its metabolites are mostly excreted via the kidneys.

Canxiol cannabidiol oral solution 150 mg/mL — Heal the way you feel. World's first prescription CBD product approved for mild to moderate anxiety disorders in conjunction with CBT.
PRESCRIBING EDUCATION RESOURCE

Prescribing Information Leaflet (PIL)

Download the document

DOWNLOAD PDF (PIL)
Available languages:English
TO BE PRESCRIBED BY
PSYCHIATRISTS ONLY

Heal the way you Feel

Anxiety is treatable – Seek Psychiatrist guidance.

Prescribing Information Leaflet

Download Official Document